Randomized trial results led to reduction in the use of minimally invasive surgery for cervical cancer

NewsGuard 100/100 Score

In a Correspondence article published in the April 29, 2021 issue of the New England Journal of Medicine, researchers from University Hospitals (UH) Cleveland Medical Center, and New York Presbyterian Hospital - Weill Cornell Medicine in New York, found a substantial reduction in the use of minimally invasive surgery for cervical cancer after publication of the results a major study called the Laparoscopic Approach to Cervical Cancer (LACC) in November 2018.

The earlier study, which compared minimally invasive surgery with open abdominal radical hysterectomy in patients with early-stage cervical cancer, found that minimally invasive surgery was associated with worse disease-free and overall survival than open surgery. As a result of that study and other related studies, many guidelines recommended that surgeons use open surgery rather than minimally invasive surgery.

In the new article, the researchers sought to answer the extent to how practice changed.

They assessed the use of minimally invasive surgery as compared with open radical hysterectomy for cervical cancer before and after publication of the LACC Trial.

They studied the records of 2,437 patients who received care at 283 medical centers between November 2015 and March 2020. About 61 percent of these patients were treated at academic centers and about 39 percent at nonacademic centers.

The percentage of hysterectomies performed with a minimally invasive approach was calculated each month, and the percentages before and after publication of the LACC Trial results were compared. A 3-month period to allow for the dissemination of the LACC Trial results was excluded from this comparison.

David Sheyn, MD, one of the authors and a gynecologist at UH Cleveland Medical Center and the UH Urology Institute, said the use of minimally invasive surgery decreased dramatically after publication of the LACC Trial.

After adjustment, the odds of minimally invasive surgery were 59 percent lower following publication of the trial results; this demonstrates a remarkably fast response to solid clinical data."

Dr. David Sheyn, MD, Author

Before the trial results were published, the minimally invasive approach was used in 58 percent of hysterectomies, as compared with 42.9 percent after publication.

Jonathan Shoag, MD, the senior author of the study and a urologic oncologist from the UH Urology Institute, said that the odds were still higher for minimally invasive surgery at a non-academic medical center compared with an academic medical center; 0.81 versus 0.27. He said the results of the new study suggests an opportunity to improve outcomes at non-academic medical centers.

Spyridon Basourakos, MD, urology resident from New York Presbyterian Hospital - Weill Cornell Medicine in New York, stated that understanding the impact of clinical trials on real-world practice patterns may help to bridge the gap between new discoveries and population-level clinical outcomes.

Source:
Journal reference:

Lewicki, P.J., et al. (2021) Effect of a Randomized, Controlled Trial on Surgery for Cervical Cancer. New England Journal of Medicine. doi.org/10.1056/NEJMc2035819.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ketone supplement boosts efficacy of prostate cancer immunotherapy